StockData

Biomerica vs ImmuCell

BMRA and ICCC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BMRA and ICCC compare

ImmuCell is the larger company, worth 17 times as much as Biomerica ($104M against $6.1M).

ImmuCell grew revenue faster over the last twelve months (8.5% versus −11.2% for Biomerica).

ImmuCell keeps more of each dollar of sales as profit, with a net margin of 2.6% compared with −115% at Biomerica.

ImmuCell scores higher on the StockData Score (13 against 8 for Biomerica), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBMRAICCC
Size and price
Market cap$6.1M$104M
Share price$1.32$11.42
Change, 1 year−47.2%88.8%
Change, 5 years−96.7%24.1%
Beta (5Y)0.840.73
Employees1773
StockData Score
Total score813 (better)
Valuation score3 (better)1
Growth score03 (better)
Performance score04 (better)
Health score55
Dividend score00
Valuation
P/E–143×
P/S1.4× (better)3.4×
P/B1.7× (better)3.3×
EV/EBITDA–16.4×
P/FCF–24.6×
FCF yield–4.1%
Fair value$2.49$11.04
Margin of safety47.0% (better)−3.4%
Growth
Revenue growth (TTM)−11.2%8.5% (better)
Revenue growth, 5Y average−9.2%12.5% (better)
Net income growth (TTM)–−55.3%
EPS growth (TTM)–−57.9%
Profitability
Gross margin0.90%40.3% (better)
Operating margin−125%12.6% (better)
Net margin−115%2.6% (better)
FCF margin–13.7%
Return on equity−114%2.6% (better)
Return on invested capital−284%11.1% (better)
Financial health
Debt / equity0.000.26 (better)
Net debt / EBITDA–−0.09
Interest coverage–8.9×
Current ratio1.914.75 (better)
Altman Z-score−10.575.10 (better)
Piotroski F-score47 (better)
Dividends and buybacks
Buyback yield−52.2%0.00% (better)
Shareholder yield−52.2%0.00% (better)
Ownership
Held by institutions2.7%14.7%
Held by insiders27.4%13.6%
Insider net buying, 12 months$158K (better)$156K
Short interest, % of float0.37%0.19%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.